Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.55 |
| ▸ | ADH1C | P00326 | 2/20 | 0.55 |
| ▸ | ADH1A | P07327 | 2/20 | 0.55 |
| ▸ | ADH4 | P08319 | 1/20 | 0.55 |
| ▸ | ADH7 | P40394 | 1/20 | 0.55 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763373 | 0.80 | ADH1B (0.71) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL2437965 | 0.77 | — | — | |
| SCHEMBL2437966 | 0.77 | — | — | |
| SCHEMBL11319997 | 0.76 | ADH1B (0.55) | ADH1BADH1CADH1AADH4ADH7 | |
| Methamoctol SCHEMBL13003427 | 0.74 | KCNH3 (0.41) | KCNH3KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL277906 | 0.74 | ADH1B (0.63) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL269775 | 0.74 | — | — | |
| SCHEMBL5003472 | 0.72 | ADH1B (0.96) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3885024 | 0.72 | ALDH1A1 (0.39) | KCNH3KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL31412818 | 0.72 | ALDH1A1 (0.39) | KCNH3KMT2AMEN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | ADH1B 1897/4885ADH1C 448/4885ADH1A 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.